版本:
中国

BRIEF-Pulmatrix says received key patent in U.S. For PUR0200

May 9 Pulmatrix Inc

* Received key patent in U.S. for its lead drug candidate, PUR0200, which is intended to treat chronic obstructive pulmonary diseases

* New patent covers PUR0200, an inhaled drug made by combining Pulmatrix's technology platform with tiotropium bromide Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐